WO2013023319A8 - Método in vitro para modificar el perfil de depleción de células t reguladoras presentes en una población total de esplenocitos de una muestra, cultivar y exponer los mismos a un medio de atp y polimixina b - Google Patents

Método in vitro para modificar el perfil de depleción de células t reguladoras presentes en una población total de esplenocitos de una muestra, cultivar y exponer los mismos a un medio de atp y polimixina b Download PDF

Info

Publication number
WO2013023319A8
WO2013023319A8 PCT/CL2012/000043 CL2012000043W WO2013023319A8 WO 2013023319 A8 WO2013023319 A8 WO 2013023319A8 CL 2012000043 W CL2012000043 W CL 2012000043W WO 2013023319 A8 WO2013023319 A8 WO 2013023319A8
Authority
WO
WIPO (PCT)
Prior art keywords
polymyxin
cells
splenocytes
atp
medium
Prior art date
Application number
PCT/CL2012/000043
Other languages
English (en)
French (fr)
Other versions
WO2013023319A1 (es
Inventor
Claudio ACUÑA
Claudio CAPELLI
Claudio CODDOU
Alejandro ESCOBAR
Monica IMARAI
Yohana LABRA
Ximena LOPEZ
Miguel Rios
Mercedes LOPEZ
Original Assignee
Universidad De Santiago De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Santiago De Chile filed Critical Universidad De Santiago De Chile
Publication of WO2013023319A1 publication Critical patent/WO2013023319A1/es
Priority to US14/181,810 priority Critical patent/US20140371159A1/en
Publication of WO2013023319A8 publication Critical patent/WO2013023319A8/es
Priority to US15/013,320 priority patent/US20160287661A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides, bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método in vitro para modificar el perfil de depleción de células Treg presentes en una población total de esplenocitos de una muestra biológica que comprende aislar, cultivar y exponer los esplenocitos a un medio de ATP y polimixina B, donde los esplenocitos son expuestos a concentraciones de Polimixina B en el rango de 0,1 μg/ml a 1.000 μg/ml, y uso combinado de Polomixina B y ATP para preparar un medicamento útil en el tratamiento de tumores o cáncer en mamíferos, donde el cáncer es melanoma.
PCT/CL2012/000043 2011-08-18 2012-08-17 Método in vitro para modificar el perfil de depleción de células treg presentes en una población total de esplenocitos de una muestra biológica al aislar, cultivar y exponer los mismos a un medio de atp y polimixina b WO2013023319A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/181,810 US20140371159A1 (en) 2011-08-18 2014-02-17 In vitro method for modifying the depletion profile of treg cells present in a total splenocyte population of a biological sample by means of the isolation, culturing and exposure thereof to an atp and polymixin b medium
US15/013,320 US20160287661A1 (en) 2011-08-18 2016-02-02 Method for treating cancer by administering atp and polymyxin b

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2020-2011 2011-08-18
CL2011002020A CL2011002020A1 (es) 2011-08-18 2011-08-18 Metodo in vitro para modificar el perfil de celulas treg presentes en una poblacion total de esplenocitos de una muestra biologica porque comprende aislar, cultivar y exponer los esplenocitos a un medio de atp y polimixina b.10 ug/ml a 100 ug/ml y uso combinado de polomixina b y atp para preparar un medicamento util en el tratamiento de tumores.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/181,810 Continuation US20140371159A1 (en) 2011-08-18 2014-02-17 In vitro method for modifying the depletion profile of treg cells present in a total splenocyte population of a biological sample by means of the isolation, culturing and exposure thereof to an atp and polymixin b medium

Publications (2)

Publication Number Publication Date
WO2013023319A1 WO2013023319A1 (es) 2013-02-21
WO2013023319A8 true WO2013023319A8 (es) 2014-03-20

Family

ID=50279004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CL2012/000043 WO2013023319A1 (es) 2011-08-18 2012-08-17 Método in vitro para modificar el perfil de depleción de células treg presentes en una población total de esplenocitos de una muestra biológica al aislar, cultivar y exponer los mismos a un medio de atp y polimixina b

Country Status (3)

Country Link
US (2) US20140371159A1 (es)
CL (1) CL2011002020A1 (es)
WO (1) WO2013023319A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049372A (en) * 1982-07-13 1991-09-17 Eliezer Rapaport Anticancer activities in a host by increasing blood and plasma adenosine 5'-triphosphate (ATP) levels
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CN1313104C (zh) 2005-05-27 2007-05-02 中国科学院南海海洋研究所 一种具有柴胡和多霉素协同作用的抗癌药物组合物

Also Published As

Publication number Publication date
US20140371159A1 (en) 2014-12-18
US20160287661A1 (en) 2016-10-06
WO2013023319A1 (es) 2013-02-21
CL2011002020A1 (es) 2012-04-20

Similar Documents

Publication Publication Date Title
BR112016014488A2 (pt) Meio para cultura celular
WO2011149762A3 (en) Method of nociceptor differentiation of human embryonic stem cells and uses thereof
CL2012003401A1 (es) Compuestos derivados de carbamato de hexafluoroisopropilo, inhibidores de la enzima monoacil glicerol lipasa (mgl); proceso de preparacion; medicamento; compuestos intermediarios; composicion farmaceutica; y su uso para tratar o prevenir dolores agudos o cronicos, vertigos, dislipidemias y epilepsia, entre otras enfermedades.
ECSP13012692A (es) Compuestos tricíclicos inhibidores de la pi3k y métodos de uso
ES2523998T3 (es) Método de aislamiento de citoblastos dérmicos
CY1120115T1 (el) Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων
IN2015DN00934A (es)
GB0916370D0 (en) Compositions
BR112013032659A2 (pt) método para o tratamento de células-tronco mesenquimais, que compreende a obtenção e o isolamento das células-tronco mesenquimais e a cultura das células em um meio de tratamento; células-tronco mesenquimais; e uso das células
BR112014031424A2 (pt) tratamento de células pluripotentes
WO2007136936A3 (en) Dermis-derived cells for tissue engineering applications
NZ609201A (en) Means and methods for treating dlbcl
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
AR083934A1 (es) Capa de pichia kluyveri y sus aplicaciones
CY1116186T1 (el) Μακροκυκλικες ενωσεις και μεθοδοι για την παραγωγη τους
Sandra et al. Conditioned media of human umbilical cord blood mesenchymal stem cell-derived secretome induced apoptosis and inhibited growth of HeLa cells
WO2013184193A3 (en) Cancer stem cells and methods of using the same
CA2837895C (en) Methods of treating or preventing neurological diseases
WO2014072720A3 (en) Cell differentiation
WO2012118349A3 (ko) 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법
MX336067B (es) Celula madre para uso terapeutico, la cual se deriva de monocito humano y metodo para inducir la misma.
WO2014100746A3 (en) Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12774914

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12774914

Country of ref document: EP

Kind code of ref document: A1